PMID- 40975105
OWN - NLM
STAT- Publisher
LR  - 20250920
IS  - 2352-3026 (Electronic)
IS  - 2352-3026 (Linking)
DP  - 2025 Sep 17
TI  - Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients 
      with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, 
      phase 2 study.
LID - S2352-3026(25)00252-2 [pii]
LID - 10.1016/S2352-3026(25)00252-2 [doi]
AB  - BACKGROUND: Bendamustine and rituximab combined with intermediate-dose cytarabine 
      (RBAC) is one of the standard initial treatments for older, fit patients with 
      mantle cell lymphoma. We aimed to investigate whether the addition of venetoclax 
      to RBAC would improve progression-free survival in patients with high-risk mantle 
      cell lymphoma. METHODS: FIL_V-RBAC was a multicentre, single-arm, phase 2 study 
      done in 35 institutions of the Fondazione Italiana Linfomi in Italy. 
      Treatment-naive patients with a histological diagnosis of mantle cell lymphoma, 
      aged 65 years or older and fit according to the Fondazione Italiana Linfomi 
      modified comprehensive geriatric assessment (or younger than 65 years and 
      ineligible for high-dose chemotherapy with Eastern Cooperative Oncology Group 
      performance status of 2 or less), were classified after enrolment as having 
      low-risk or high-risk disease, based on the presence of blastoid morphology, Ki67 
      30% or higher, TP53, or 17p deletion. Patients with a low-risk profile received 
      RBAC intravenously (rituximab 375 mg/m(2) and day 1; bendamustine 70 mg/m(2) on 
      days 1 and 2; and cytarabine 500 mg/m(2) on days 1, 2, and 3) every 4 weeks for 6 
      cycles. Patients with a high-risk profile received four cycles of RBAC followed 
      by fixed-duration oral venetoclax consolidation (4 months, 800 mg/day) and 
      maintenance (20 months, 400 mg/day). The primary endpoint was 2-year 
      progression-free survival for patients with a high-risk profile who received at 
      least one dose of RBAC. This trial was registered with ClinicalTrials.gov, 
      NCT03567876, and this is the final report. FINDINGS: Between Sept 10, 2018, and 
      July 26, 2021, 155 patients were screened for inclusion, 140 of whom were 
      enrolled and analysed for study endpoints. Median age was 72 (IQR 69-76), 107 
      (76%) patients were male, 33 (24%) were female, and all were White. 54 (39%) 
      patients had a high-risk profile (28 [20%] with TP53 mutations, 19 [14%] with 17p 
      deletions, 34 [24%] with Ki67 ≥30%, and 13 [9%] with a blastoid morphology) and 
      86 (61%) had a low-risk profile. After a median follow-up of 45 months (IQR 
      40-55), the 2-year progression-free survival in the high-risk group was 60% (95% 
      CI 48-74) and the median progression-free survival was 37 months (95% CI 19-not 
      reached). The most frequent grade 3 or worse adverse events during venetoclax 
      consolidation were neutropenia (12 [28%] of 43 patients), followed by 
      thrombocytopenia (three [7%]) and skin reactions (three [7%]). During venetoclax 
      maintenance, the most frequent grade 3 or worse adverse events were neutropenia 
      (seven [19%] of 37 patients), followed by thrombocytopenia (two [5%]) and anaemia 
      (two [5%]). One (1%) of 140 patients had a treatment-related death (tumour lysis 
      syndrome during first induction with RBAC in a patient with a high-risk profile). 
      INTERPRETATION: To our knowledge, this is the first prospective study to stratify 
      patients with mantle cell lymphoma to different treatments according to their 
      risk profile. Our results suggest that the addition of fixed-duration venetoclax 
      improves the performance of RBAC in patients with a high-risk disease profile. 
      Our findings point to the importance of identifying patients with high-risk 
      disease at initial diagnosis. FUNDING: Fondazione Italiana Linfomi-Ente del Terzo 
      Settore, Leukemia and Lymphoma Society, and Ministry of Health, Italy, and 
      AbbVie. TRANSLATION: For the Italian translation of the abstract see 
      Supplementary Materials section.
CI  - Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and 
      data mining, AI training, and similar technologies.
FAU - Visco, Carlo
AU  - Visco C
AD  - Dipartimento di Ingegneria per la Medicina di Innovazione, Ematologia, Università 
      di Verona, Verona, Italy. Electronic address: carlo.visco@univr.it.
FAU - Tabanelli, Valentina
AU  - Tabanelli V
AD  - IRCCS Istituto Europeo di Oncologia, Ematopatologia, Milan, Italy.
FAU - Sacchi, Maria Vittoria
AU  - Sacchi MV
AD  - Fondazione Italiana Linfomi ETS, sede di Alessandria, Alessandria, Italy.
FAU - Evangelista, Andrea
AU  - Evangelista A
AD  - Azienda Ospedaliera Città della Salute e della Scienza, Unità di Epidemiologia 
      Clinica, CPO, Turin, Italy.
FAU - Quaglia, Francesca Maria
AU  - Quaglia FM
AD  - Dipartimento di Ingegneria per la Medicina di Innovazione, Ematologia, Università 
      di Verona, Verona, Italy.
FAU - Fiori, Stefano
AU  - Fiori S
AD  - IRCCS Ca Granda, Ospedale Maggiore Policlinico, Divisione di Patologia, Milan, 
      Italy.
FAU - Bomben, Riccardo
AU  - Bomben R
AD  - IRCCS Centro di Riferimento Oncologico (CRO) di Aviano, Aviano, Italy.
FAU - Tisi, Maria Chiara
AU  - Tisi MC
AD  - ULSS 8-Berica-Ospedale San Bortolo, Ematologia, Vicenza, Italy.
FAU - Riva, Marcello
AU  - Riva M
AD  - ULSS 8-Berica-Ospedale San Bortolo, Ematologia, Vicenza, Italy.
FAU - Merli, Anna
AU  - Merli A
AD  - Ospedale degli Infermi, Ematologia, Rimini, Italy.
FAU - Rotondo, Francesco
AU  - Rotondo F
AD  - Ospedale degli Infermi, Ematologia, Rimini, Italy.
FAU - Fraenza, Costanza
AU  - Fraenza C
AD  - Dipartimento di Ingegneria per la Medicina di Innovazione, Ematologia, Università 
      di Verona, Verona, Italy.
FAU - Carazzolo, Maria Elena
AU  - Carazzolo ME
AD  - Dipartimento di Ingegneria per la Medicina di Innovazione, Ematologia, Università 
      di Verona, Verona, Italy.
FAU - Corradini, Paolo
AU  - Corradini P
AD  - IRCCS Istituto Nazionale dei Tumori, Ematologia, Milan, Italy.
FAU - Farina, Lucia
AU  - Farina L
AD  - IRCCS Istituto Nazionale dei Tumori, Ematologia, Milan, Italy.
FAU - Castellino, Claudia
AU  - Castellino C
AD  - Azienda Ospedaliera Santa Croce e Carle, Ematologia e TMO, Cuneo, Italy.
FAU - Castellino, Alessia
AU  - Castellino A
AD  - Azienda Ospedaliera Santa Croce e Carle, Ematologia e TMO, Cuneo, Italy.
FAU - Zilioli, Vittorio Ruggero
AU  - Zilioli VR
AD  - Azienda Socio-Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, 
      Divisione di Ematologia, Milan, Italy.
FAU - Muzi, Cristina
AU  - Muzi C
AD  - Azienda Socio-Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, 
      Divisione di Ematologia, Milan, Italy.
FAU - Piazza, Francesco
AU  - Piazza F
AD  - Università di Padova, Dipartimento di Medicina, Unità di Ematologia, Padua, 
      Italy.
FAU - Re, Alessandro
AU  - Re A
AD  - ASST Spedali Civili di Brescia, Ematologia, Brescia, Italy.
FAU - Hohaus, Stefan
AU  - Hohaus S
AD  - IRCCS Policlinico Universitario Gemelli, Ematologia e Università del Sacro Cuore, 
      Rome, Italy.
FAU - Rossi, Francesca Gaia
AU  - Rossi FG
AD  - IRCCS Ca Granda, Ospedale Maggiore Policlinico, Ematologia, Milan, Italy.
FAU - Musuraca, Gerardo
AU  - Musuraca G
AD  - IRCCS Istituto Romagnolo per lo studio dei Tumori, Dino Amadori, Ematologia, 
      Meldola.
FAU - Di Rocco, Alice
AU  - Di Rocco A
AD  - Policlinico Umberto I, Università La Sapienza, Dipartimento di Medicina 
      Traslazionale e di Precisione, Ematologia, Rome, Italy.
FAU - Puccini, Benedetta
AU  - Puccini B
AD  - Azienda Ospedaliero Universitaria Careggi, Ematologia, Florence, Italy.
FAU - Sciarra, Roberta
AU  - Sciarra R
AD  - IRCCS Policlinico San Matteo, Ematologia, Pavia, Italy.
FAU - Ballerini, Filippo
AU  - Ballerini F
AD  - IRCCS Ospedale Policlinico San Martino, Clinica Ematologica, Genoa, Italy.
FAU - Cavallo, Federica
AU  - Cavallo F
AD  - Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Ematologia 
      Universitaria and Dipartimento di Biotecnologie Molecolari e Scienze della 
      Salute, Università di Torino, Turin, Italy.
FAU - Bruna, Riccardo
AU  - Bruna R
AD  - Azienda Ospedaliero Universitaria Maggiore della Carità, SCDU Ematologia, Novara, 
      Italy.
FAU - Moia, Riccardo
AU  - Moia R
AD  - Azienda Ospedaliero Universitaria Maggiore della Carità, SCDU Ematologia, Novara, 
      Italy.
FAU - Moioli, Alessia
AU  - Moioli A
AD  - Dipartimento di Ingegneria per la Medicina di Innovazione, Ematologia, Università 
      di Verona, Verona, Italy.
FAU - Bernardelli, Andrea
AU  - Bernardelli A
AD  - Dipartimento di Ingegneria per la Medicina di Innovazione, Ematologia, Università 
      di Verona, Verona, Italy.
FAU - Drandi, Daniela
AU  - Drandi D
AD  - Azienda Ospedaliero Universitaria Città della Salute e della Scienza, Ematologia 
      Universitaria and Dipartimento di Biotecnologie Molecolari e Scienze della 
      Salute, Università di Torino, Turin, Italy.
FAU - Arcari, Annalisa
AU  - Arcari A
AD  - Ospedale Guglielmo da Saliceto, Ematologia, Piacenza, Italy.
FAU - Merli, Francesco
AU  - Merli F
AD  - IRCCS Azienda Sanitaria Locale, Ematologia, Reggio Emilia, Italy.
FAU - Gini, Guido
AU  - Gini G
AD  - Azienda Ospedaliero Universitaria delle Marche-Università Politecnica delle 
      Marche, Ematologia, Ancona, Italy.
FAU - Freilone, Roberto
AU  - Freilone R
AD  - Azienda Ospedaliero Universitaria Città della Salute e della Scienza, SC 
      Ematologia, Turin, Italy.
FAU - Tani, Monica
AU  - Tani M
AD  - Ospedale Santa Maria delle Croci, Ematologia, Ravenna, Italy.
FAU - Pavone, Vincenzo
AU  - Pavone V
AD  - Azienda Ospedaliera Fondazione Cardinale Panìco, Ematologia e TMO, Tricase, 
      Italy.
FAU - Ladetto, Marco
AU  - Ladetto M
AD  - Università del Piemonte Orientale, Dipartimento di Medicina Traslazionale, e 
      Azienda Ospedaliero Universitaria SS Antonio e Biagio e Cesare Arrigo, 
      Ematologia, Alessandria, Italy.
FAU - Pileri, Stefano Aldo
AU  - Pileri SA
AD  - IRCCS Istituto Europeo di Oncologia, Ematopatologia, Milan, Italy.
FAU - Balzarotti, Monica
AU  - Balzarotti M
AD  - IRCCS Istituto Clinico Humanitas, Ematologia, Rozzano, Italy.
CN  - Fondazione Italiana Linfomi
LA  - eng
SI  - ClinicalTrials.gov/NCT03567876
PT  - Journal Article
DEP - 20250917
PL  - England
TA  - Lancet Haematol
JT  - The Lancet. Haematology
JID - 101643584
SB  - IM
COIS- Declaration of interests CV reports support for the study from the Leukemia & 
      Lymphoma Society (award number MCL7005–24); payment or honoraria for lectures or 
      presentations from AbbVie, Bristol Myers Squibb, AstraZeneca, Servier, Incyte, 
      Roche, Pfizer, Novartis, Gentili, Janssen, Kite-Gilead, BeiGene, Lilly, and Kyowa 
      Kirin; support for attending meetings and/or travel from AbbVie, Bristol Myers 
      Squibb, AstraZeneca, Servier, Incyte, Roche, Pfizer, Novartis, Gentili, Janssen, 
      Kite-Gilead, BeiGene, Lilly, Kyowa Kirin, and Johnson & Johnson; and 
      participation on a data safety monitoring board or advisory board from AbbVie, 
      Bristol Myers Squibb, Incyte, Roche, Pfizer, and Johnson & Johnson. FMQ reports 
      payment or honoraria for lectures or presentations from AstraZeneca and 
      Kite-Gilead; support for attending meetings and/or travel from Novartis, Roche, 
      and GSK; and consultant with no compensation for Sandoz. PC reports payment or 
      honoraria for lectures, presentations, and educational events from AbbVie, Amgen, 
      BeiGene, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead/Kite, GSK, 
      Incyte, Janssen, Jazz Pharma, Novartis, Pfizer, Roche, Sanofi, SOBI, and Takeda; 
      support for attending meetings and/or travel from AbbVie, Amgen, Bristol Myers 
      Squibb, Gilead/Kite, Janssen, Novartis, Roche, and Takeda; and participation on a 
      data safety monitoring board or advisory board from AbbVie, Amgen, BeiGene, 
      Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead/Kite, GSK, Incyte, 
      Janssen, Jazz Pharma, Novartis, Pfizer, Roche, Sanofi, SOBI, and Takeda. LF 
      reports payment or honoraria for lectures or presentations from BeiGene, AbbVie, 
      and Janssen. AC reports payment or honoraria for lectures or presentations from 
      Kite/Gilead, Roche, and Gentili; and support for attending meetings and/or travel 
      from Roche and Kite/Gilead. VRZ reports support with grants or contracts from 
      Kite/Gilead; consulting fees from Roche; payment or honoraria for lectures or 
      presentations from Incyte, Janssen, Lilly, SOBI, and Takeda; support for 
      attending meetings and/or travel from BeiGene, Janssen, Roche, and Takeda; and 
      participation on a data safety monitoring board or advisory board from AbbVie, 
      AstraZeneca, Kite/Gilead, Novartis, Roche, SOBI, and Takeda. FP reports payment 
      or honoraria for lectures or presentations from Roche, Lilly, Kite/Gilead, 
      Janssen, SOBI, and AbbVie; support for attending meetings and/or travel from 
      Roche, Lilly, Kite/Gilead, Janssen, SOBI, and AbbVie; and participation on a data 
      safety monitoring board or advisory board from Roche, AbbVie, SOBI, and Lilly. AR 
      reports payment from AbbVie and participation on an advisory board from AbbVie. 
      SH reports consulting fees from AbbVie, BeiGene, Bristol Myers Squibb, Incyte, 
      Ipsen, Lilly, Roche, Takeda, Gilead, and Novartis; and support for attending 
      meetings and/or travel from Roche, Gilead, and Takeda. FGR reports participation 
      on a data safety monitoring board or advisory board from Takeda, Incyte, and 
      Johnson & Johnson. ADR reports consulting fees from Roche, Incyte, Kite, 
      Novartis, AbbVie, and SOBI; payment or honoraria for lectures or presentations 
      from Roche, Incyte, Kite, Novartis, AbbVie, Ely Lilly, Johnson & Johnson, SOBI, 
      and Bristol Myers Squibb; support for attending meetings and/or travel from Kite, 
      BeiGene, and AbbVie. RS reports participation on a data safety monitoring board 
      or advisory board from Incyte. AB reports payment or honoraria for lectures or 
      presentations from Roche, Kyowa Kirin, and Takeda. GM reports consulting fees, 
      payment or honoraria for lectures or presentations, payment for expert testimony, 
      support for attending meetings and/or travel, participation on a data safety 
      monitoring board or advisory board, and leadership or fiduciary role in other 
      board, society, committee, or advocacy group from AbbVie. FM reports payment or 
      honoraria for lectures or presentations from AstraZeneca, Roche, Sandoz, Incyte, 
      Gilead, and Novartis; support for attending meetings and/or travel from Kite, 
      Gilead, BeiGene, Takeda, and Sandoz; participation on a data safety monitoring 
      board or advisory board from Takeda, Janssen, and Gilead; and leadership or 
      fiduciary role in other board, society, committee, or advocacy group for 
      Fondazione Italiana Linfomi, unpaid. GG reports consulting fees from Takeda, 
      Roche, Lilly, Gilead, Incyte, AbbVie, SOBI, and BeiGene; payment or honoraria for 
      lectures or presentations from Takeda, Roche, and Incyte; support for attending 
      meetings and/or travel from Roche and Takeda; and participation on a data safety 
      monitoring board or advisory board from Takeda, Roche, and AbbVie. RF reports 
      payment or honoraria for lectures or presentations from Kite, SOBI, Incyte, and 
      Novartis. ML reports payment or honoraria for lectures or presentations from 
      AbbVie, Acerta, Amgen, ADC Therapeutics, BeiGene, Celgene/Bristol Myers Squibb, 
      Eusapharma, GSKI, Gentili, Gilead/Kite, Novartis, Incyte, Johnson & Johnson, 
      Jazz, Lilly, Regeneron, Roche, and Sandoz; and participation on a data safety 
      monitoring board or advisory board from Regeneron. MB reports consulting fees 
      from Roche and SOBI; payment or honoraria for lectures or presentations from 
      Roche, SOBI, Eli Lilly, Gilead, BeiGene, AstraZeneca, and AbbVie; and support for 
      attending meetings and/or travel from Roche and BeiGene. All other authors 
      declare no competing interests.
EDAT- 2025/09/21 00:30
MHDA- 2025/09/21 00:30
CRDT- 2025/09/20 18:53
PHST- 2025/04/28 00:00 [received]
PHST- 2025/08/08 00:00 [revised]
PHST- 2025/08/20 00:00 [accepted]
PHST- 2025/09/21 00:30 [medline]
PHST- 2025/09/21 00:30 [pubmed]
PHST- 2025/09/20 18:53 [entrez]
AID - S2352-3026(25)00252-2 [pii]
AID - 10.1016/S2352-3026(25)00252-2 [doi]
PST - aheadofprint
SO  - Lancet Haematol. 2025 Sep 17:S2352-3026(25)00252-2. doi: 
      10.1016/S2352-3026(25)00252-2.
